GGrantIndex
← Leaderboards

Lisa Rimsza

University Of Rochester

$10,310,313
Attributed
$16,285,950
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.9M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$26,523,943 · 8

By mechanism

P01$11,414,331 · 2
UM1$8,686,983 · 1
U01$3,062,767 · 1
P50$1,572,172 · 1
UH3$1,021,903 · 1
UH2$765,787 · 2

Top collaborators

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Lymphoma

Research focus

LymphomaProgramsDiagnosisTissuesDiagnosticClinical TrialsEnsurePathologicSiteLaboratoriesEvaluationMalignant NeoplasmsResourcesBiopsyMolecularFreezingTherapeutic TargetMolecular DiagnosisLeukemia/LymphomaPrincipal InvestigatorResearch PersonnelBaseLeadershipMolecular Profiling

Grant awards (29)

AIDS and Cancer Specimen Resource (ACSR)$3,963,281
UM1 · FY2025 · CA
Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma$161,663
UH2 · FY2025 · CA · contact PI
AIDS and Cancer Specimen Resource (ACSR)$4,723,702
UM1 · FY2024 · CA
Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma$206,968
UH2 · FY2024 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$1,913,660
P01 · FY2022 · CA · contact PI
Administrative Core$176,422
P01 · FY2022 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$2,117,897
P01 · FY2021 · CA · contact PI
Development of Mantle Cell Lymphoma Proliferation Signature Assay$344,075
UH3 · FY2021 · CA · contact PI
Administrative Core$276,090
P01 · FY2021 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$2,112,284
P01 · FY2020 · CA · contact PI
Development of Mantle Cell Lymphoma Proliferation Signature Assay$344,075
UH3 · FY2020 · CA · contact PI
Administrative Core$276,090
P01 · FY2020 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$2,006,791
P01 · FY2019 · CA · contact PI
Development of Mantle Cell Lymphoma Proliferation Signature Assay$333,753
UH3 · FY2019 · CA · contact PI
Administrative Core$173,134
P01 · FY2019 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$2,087,361
P01 · FY2018 · CA · contact PI
Administrative Core$274,602
P01 · FY2018 · CA · contact PI
Development of Mantle Cell Lymphoma Proliferation Signature Assay$198,578
UH2 · FY2018 · CA · contact PI
Development of Mantle Cell Lymphoma Proliferation Signature Assay$198,578
UH2 · FY2017 · CA · contact PI
Molecular Diagnosis and Prognosis in Aggressive Lymphoma$841,820
U01 · FY2015 · CA · contact PI
Molecular Diagnosis and Prognosis in Aggressive Lymphoma$565,864
U01 · FY2014 · CA · contact PI
Molecular Diagnosis and Prognosis in Aggressive Lymphoma$460,703
U01 · FY2013 · CA · contact PI
Molecular Diagnosis and Prognosis in Aggressive Lymphoma$594,380
U01 · FY2012 · CA · contact PI
CB: Tissue Core$323,641
P50 · FY2012 · CA · contact PI
Molecular Diagnosis and Prognosis in Aggressive Lymphoma$600,000
U01 · FY2011 · CA · contact PI
CB: Tissue Core$306,944
P50 · FY2011 · CA · contact PI
CB: Tissue Core$323,443
P50 · FY2010 · CA · contact PI
CB: Tissue Core$363,518
P50 · FY2009 · CA · contact PI
CB: Tissue Core$254,626
P50 · FY2008 · CA · contact PI